ID   LAPC4-PDR1
AC   CVCL_C0RQ
SY   LAPC4 PDR1; L4-PDR1
DR   cancercelllines; CVCL_C0RQ
DR   GEO; GSM2649993
DR   GEO; GSM2649994
DR   GEO; GSM2649995
DR   GEO; GSM2649996
DR   GEO; GSM2649997
DR   GEO; GSM2649998
DR   PRIDE; PXD006561
DR   Wikidata; Q112929984
RX   PubMed=29739788;
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:85993; Palbociclib (Ibrance).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4744 ! LAPC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 6
//
RX   PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410;
RA   de Leeuw R., McNair C., Schiewer M.J., Poudel-Neupane N., Brand L.J.,
RA   Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M.,
RA   Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M.,
RA   Kelly W.K., Knudsen K.E.;
RT   "MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.";
RL   Clin. Cancer Res. 24:4201-4214(2018).
//